Zen graphene solutions have announced its’ development of a graphene-based antibiotic, antifungal, and antiviral compound, according to Graphene Info.
This compound was called a “…novel solution that could have an impact on infectious disease management…” by Greg Fenton, CEO. Dr. Tony Mazzulli, who conducted testing further explains it as so; ” This Graphene Compound (GC) appears to be active against both gram positive (e.g. Streptococci and Staphylococci) and gram negative (e.g. E. coli, H. influenzae, M. catarrhalis) bacteria as well as common yeast (e.g. Candida albicans) at extremely low concentrations. These results are promising. Additional testing against a broader range of bacterial species is required to determine the full spectrum of activity of this GC.”
Throughout testing, the graphene compound had a 99.9% efficiency against gram-positive and negative aerobic bacteria, and a 99.9% efficiency against Candida Albicans, or fungus/yeast.
Zen filed a provisional patent on the compounds, and will continue additional testing in order to completely understand its capabilities.